Tekla Life Sciences Investors (NYSE:HQL) — Market Cap & Net Worth
Market Cap & Net Worth: Tekla Life Sciences Investors (HQL)
Tekla Life Sciences Investors (NYSE:HQL) has a market capitalization of $595.69 Million ($595.69 Million) as of September 22, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #11493 globally and #2948 in its home market, demonstrating a -0.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tekla Life Sciences Investors's stock price $19.59 by its total outstanding shares 30408047 (30.41 Million). Also see HQL total asset value for a full breakdown of the balance sheet.
Tekla Life Sciences Investors Market Cap History: 2015 to 2026
Tekla Life Sciences Investors's market capitalization history from 2015 to 2026. Data shows growth from $307.29 Million to $595.69 Million (6.13% CAGR). Also see Tekla Life Sciences Investors cash flow conversion for how efficiently the company converts equity into cash flow.
Tekla Life Sciences Investors Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tekla Life Sciences Investors's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check HQL stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.91x
Tekla Life Sciences Investors's market cap is 5.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
5.96x
Tekla Life Sciences Investors's market cap is 5.96 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $247.50 Million | $6.29 Million | -$11.91 Million | 39.34x | N/A |
| 2017 | $310.63 Million | $69.81 Million | $68.56 Million | 4.45x | 4.53x |
| 2018 | $260.37 Million | $1.99 Million | $28.66 Million | 131.11x | 9.08x |
| 2019 | $326.85 Million | $-69.34 Million | -$70.48 Million | -4.71x | N/A |
| 2020 | $404.38 Million | $124.08 Million | $123.05 Million | 3.26x | 3.29x |
| 2021 | $426.72 Million | $65.69 Million | $64.53 Million | 6.50x | 6.61x |
| 2022 | $344.74 Million | $-103.25 Million | -$104.60 Million | -3.34x | N/A |
| 2023 | $359.33 Million | $23.52 Million | $22.35 Million | 15.28x | 16.08x |
| 2024 | $398.95 Million | $86.69 Million | $85.30 Million | 4.60x | 4.68x |
| 2025 | $510.25 Million | $86.39 Million | $85.59 Million | 5.91x | 5.96x |
Competitor Companies of HQL by Market Capitalization
Companies near Tekla Life Sciences Investors in the global market cap rankings as of September 22, 2026. Review HQL intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Tekla Life Sciences Investors by market ranking:
- BlackRock Inc (NYSE:BLK): Ranked #140 globally with a market cap of $167.86 Billion USD.
- Blackstone Group Inc (NYSE:BX): Ranked #275 globally with a market cap of $95.14 Billion USD.
- KKR & Co. Inc. (NYSE:KKR): Ranked #296 globally with a market cap of $90.51 Billion USD.
- Brookfield Corporation (TO:BN): Ranked #307 globally with a market cap of $86.65 Billion USD ( CA$119.79 Billion CAD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #140 | BlackRock Inc | NYSE:BLK | $167.86 Billion | $1090.27 |
| #275 | Blackstone Group Inc | NYSE:BX | $95.14 Billion | $126.41 |
| #296 | KKR & Co. Inc. | NYSE:KKR | $90.51 Billion | $100.83 |
| #307 | Brookfield Corporation | TO:BN | $86.65 Billion | CA$53.37 |
Tekla Life Sciences Investors Historical Marketcap From 2015 to 2026
Between 2015 and today, Tekla Life Sciences Investors's market cap moved from $307.29 Million to $ 595.69 Million, with a yearly change of 6.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $595.69 Million | +16.75% |
| 2025 | $510.25 Million | +27.90% |
| 2024 | $398.95 Million | +11.03% |
| 2023 | $359.33 Million | +4.23% |
| 2022 | $344.74 Million | -19.21% |
| 2021 | $426.72 Million | +5.52% |
| 2020 | $404.38 Million | +23.72% |
| 2019 | $326.85 Million | +25.53% |
| 2018 | $260.37 Million | -16.18% |
| 2017 | $310.63 Million | +25.51% |
| 2016 | $247.50 Million | -19.46% |
| 2015 | $307.29 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 22nd, 2026 the market cap of Tekla Life Sciences Investors was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $595.69 Million USD |
| MoneyControl | $595.69 Million USD |
| MarketWatch | $595.69 Million USD |
| marketcap.company | $595.69 Million USD |
| Reuters | $595.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more